Vertex Pharmaceuticals Incorporated (VRTX)
-NasdaqGS 77.72 
0.89(1.16%) 4:00PM EDT|After Hours
:
77.53 0.19 (0.24%) 4:31PM EDT
| Prev Close: | 76.83 |
|---|
| Open: | 76.43 |
|---|
| Bid: | 77.01 x 200 |
|---|
| Ask: | 77.69 x 100 |
|---|
| 1y Target Est: | 89.78 |
|---|
| Beta: | 0.27 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 76.16 - 78.04 |
|---|
| 52wk Range: | 37.27 - 87.47 |
|---|
| Volume: | 2,159,307 |
|---|
| Avg Vol (3m): | 2,328,740 |
|---|
| Market Cap: | 16.96B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.51 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Gilead's HCV Drug Pipeline Outshines Weak Q1 Resultsat Investor's Business Daily(Thu 6:36PM EDT)
- Gilead Misses Analysts’ Estimates on Sales of HIV Drugsat Bloomberg(Thu 4:22PM EDT)
- Vertex Q1 Results Worse Than 2012, but Better Than Expectedat Motley Fool(Thu 2:06AM EDT)
- Take 2 Dividend Stocks and Call Me in the Morningat Motley Fool(Wed, May 1)
- Why BioMarin, Catalyst Pharmaceutical Partners And Vertex Are Expected To Outperformat Seeking Alpha(Wed, May 1)
- Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan Drugs: A Wall Street Transcript Interview with Boris Peaker, Executive Director and Senior Analyst at Oppenheimer & Co. Inc.Wall Street Transcript(Wed, May 1)
- 3 Healthcare Picks From Janus Fundat Motley Fool(Wed, May 1)
- Vertex Loss Lower, Kalydeco Outlook UpZacks(Wed, May 1)
- Vertex Pharmaceuticals Incorporated Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Tue, Apr 30)
- Vertex Pharmaceuticals Earnings: Here’s Why Shares are Up Nowat Wall St. Cheat Sheet(Tue, Apr 30)
- UPDATE 1-Vertex posts loss, raises cystic fibrosis drug sales viewat Reuters(Tue, Apr 30)
- InPlay: Vertex Pharm beats by $0.09, beats on revs; guides FY13 revs in-lineBriefing.com(Tue, Apr 30)
- Vertex posts quarterly loss as hepatitis C drug sales fallat Reuters(Tue, Apr 30)
- Vertex Reports First Quarter 2013 Financial Results and Reviews Recent Progress in Development Programs for Cystic Fibrosis and Hepatitis CBusiness Wire(Tue, Apr 30)
- VERTEX PHARMACEUTICALS INC / MA Files SEC form 8-K, Results of Operations and Financial ConditionEDGAR Online(Tue, Apr 30)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 10.98 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.97 |
|---|
| Quarterly EPS Est
(Mar-13)
: | -0.19 |
|---|
| Mean Recommendation*: | 1.9 |
|---|
| PEG Ratio (5 yr expected): | -12.74 |
|---|
Business Summary
Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases.
View More